RARE
Ultragenyx Pharmaceutical Inc. NASDAQ Listed Jan 31, 2014$29.03
+5.79%
vs $27.44
Mkt Cap $2.9B
52w Low $18.50
45.9% of range
52w High $41.44
50d MA $24.42
200d MA $27.02
P/E (TTM)
-4.8x
EV/EBITDA
—
P/B
—
Debt/Equity
-15.9x
ROE
718.8%
P/FCF
-6.1x
RSI (14)
74.10
ATR (14)
$1.27
Beta
0.25
50d MA
$24.42
200d MA
$27.02
Avg Volume
1.7M
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
60 Leveroni Court · Novato, CA 94949 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | -1.50 | -1.84 | -22.9% | 25.01 | +3.6% | +3.7% | +0.8% | -0.0% | +0.7% | +2.1% | — |
| Feb 12, 2026 | AMC | -1.20 | -1.29 | -7.5% | 23.50 | -8.3% | -12.7% | -1.7% | +1.3% | +6.7% | +4.1% | — |
| Nov 4, 2025 | AMC | -1.23 | -1.81 | -47.2% | 32.46 | -11.0% | -1.8% | -2.9% | -1.0% | +4.3% | +4.1% | — |
| Aug 5, 2025 | AMC | -1.27 | -1.17 | +7.9% | 28.92 | -1.5% | -3.0% | -0.8% | -1.0% | -0.5% | +2.6% | — |
| May 6, 2025 | AMC | -1.54 | -1.57 | -1.9% | 35.06 | +1.7% | -4.7% | +7.7% | -2.4% | +2.8% | -1.9% | — |
| Feb 13, 2025 | AMC | -1.32 | -1.39 | -5.3% | 43.52 | +2.3% | -2.4% | +2.7% | +1.5% | +0.4% | -4.2% | — |
| Nov 5, 2024 | AMC | -1.45 | -1.40 | +3.4% | 52.18 | +0.7% | -3.2% | -0.2% | -0.1% | +0.7% | -5.7% | — |
| Aug 1, 2024 | AMC | -1.64 | -1.52 | +7.3% | 44.15 | +6.9% | +14.3% | -2.8% | +1.4% | -1.7% | +2.8% | — |
| May 2, 2024 | AMC | -1.72 | -2.03 | -18.0% | 43.20 | +3.9% | -1.0% | +0.6% | -2.4% | -1.0% | -0.8% | — |
| Feb 15, 2024 | AMC | -1.65 | -1.52 | +7.9% | 46.26 | +1.6% | +5.8% | -2.1% | +0.6% | +1.5% | +1.2% | — |
| Nov 2, 2023 | AMC | -2.08 | -2.23 | -7.2% | 36.60 | +0.5% | +6.1% | -2.7% | +0.8% | -4.8% | -3.6% | — |
| Aug 3, 2023 | AMC | -2.11 | -2.25 | -6.6% | 41.30 | -0.5% | -8.8% | -4.1% | -2.6% | +4.7% | -0.8% | — |
| May 4, 2023 | AMC | -1.97 | -2.33 | -18.3% | 45.81 | -4.0% | +3.1% | -0.4% | +0.0% | +3.2% | -3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $54.46 | $54.04 | -0.8% | +0.6% | -0.2% | +0.2% | -1.8% | -1.4% |
| Oct 21 | TD Cowen | Maintains | Buy → Buy | — | $56.26 | $56.16 | -0.2% | -3.2% | +0.6% | -0.2% | +0.2% | -1.8% |
| Oct 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $55.55 | $55.58 | +0.1% | +1.7% | -1.7% | -3.4% | +0.2% | -2.5% |
| Sep 26 | RBC Capital | Maintains | Outperform → Outperform | — | $56.76 | $56.99 | +0.4% | -2.7% | -1.4% | +2.1% | +1.7% | -1.7% |
| Sep 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $58.78 | $58.78 | +0.0% | -0.1% | -2.0% | -0.1% | -1.3% | -2.7% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $58.74 | $59.37 | +1.1% | +1.1% | -1.5% | -1.4% | +1.9% | -0.1% |
| Aug 5 | Barclays | Maintains | Overweight → Overweight | — | $50.47 | $46.96 | -7.0% | -2.8% | +1.4% | -1.7% | +2.8% | -0.5% |
| Aug 2 | Wells Fargo | Maintains | Overweight → Overweight | — | $44.15 | $47.20 | +6.9% | +14.3% | -2.8% | +1.4% | -1.7% | +2.8% |
| Aug 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $44.15 | $47.20 | +6.9% | +14.3% | -2.8% | +1.4% | -1.7% | +2.8% |
| Aug 2 | Goldman Sachs | Maintains | Buy → Buy | — | $44.15 | $47.20 | +6.9% | +14.3% | -2.8% | +1.4% | -1.7% | +2.8% |
| Aug 2 | Wedbush | Maintains | Neutral → Neutral | — | $44.15 | $47.20 | +6.9% | +14.3% | -2.8% | +1.4% | -1.7% | +2.8% |
| Jul 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $44.46 | $44.47 | +0.0% | +1.6% | -0.2% | -0.1% | -0.4% | +0.8% |
| Jul 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $42.55 | $42.95 | +0.9% | +4.5% | +1.6% | -0.2% | -0.1% | -0.4% |
| Jul 18 | Wedbush | Maintains | Neutral → Neutral | — | $43.89 | $43.82 | -0.2% | -2.5% | -0.5% | +4.5% | +1.6% | -0.2% |
| Jun 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.40 | $42.60 | +2.9% | +7.8% | -3.4% | -9.4% | +1.9% | -6.0% |
| Jun 6 | Goldman Sachs | Upgrade | Neutral → Buy | — | $41.45 | $43.78 | +5.6% | +0.8% | -0.9% | +1.4% | -1.4% | +7.8% |
| May 31 | Stifel | Maintains | Buy → Buy | — | $38.65 | $39.47 | +2.1% | +3.9% | +2.5% | -0.5% | +1.3% | +0.8% |
| May 31 | Baird | Maintains | Outperform → Outperform | — | $38.65 | $39.47 | +2.1% | +3.9% | +2.5% | -0.5% | +1.3% | +0.8% |
| May 31 | BofA Securities | Maintains | Buy → Buy | — | $38.65 | $39.47 | +2.1% | +3.9% | +2.5% | -0.5% | +1.3% | +0.8% |
| May 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $38.65 | $39.47 | +2.1% | +3.9% | +2.5% | -0.5% | +1.3% | +0.8% |
| May 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $38.65 | $39.47 | +2.1% | +3.9% | +2.5% | -0.5% | +1.3% | +0.8% |
| May 31 | Wedbush | Maintains | Neutral → Neutral | — | $38.65 | $39.47 | +2.1% | +3.9% | +2.5% | -0.5% | +1.3% | +0.8% |
| May 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $42.75 | $42.77 | +0.0% | +0.6% | -2.4% | -1.0% | -0.8% | -0.8% |
| May 3 | Wedbush | Maintains | Neutral → Neutral | — | $43.20 | $44.88 | +3.9% | -1.0% | +0.6% | -2.4% | -1.0% | -0.8% |
| May 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $43.20 | $44.88 | +3.9% | -1.0% | +0.6% | -2.4% | -1.0% | -0.8% |
| Apr 24 | TD Cowen | Maintains | Buy → Buy | — | $45.11 | $45.52 | +0.9% | -1.8% | -1.0% | +0.9% | -0.5% | -3.4% |
| Apr 17 | Wedbush | Maintains | Neutral → Neutral | — | $42.31 | $42.26 | -0.1% | +4.3% | -1.7% | -2.3% | +3.1% | +3.3% |
| Apr 16 | Wedbush | Maintains | Neutral → Neutral | — | $42.87 | $42.85 | -0.0% | -1.3% | +4.3% | -1.7% | -2.3% | +3.1% |
| Apr 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $47.08 | $46.59 | -1.0% | +6.7% | -0.0% | +0.7% | +2.1% | -1.8% |
| Mar 18 | JP Morgan | Maintains | Overweight → Overweight | — | $47.37 | $47.94 | +1.2% | -1.6% | +0.9% | +0.0% | -0.8% | -1.7% |
| Feb 27 | JP Morgan | Maintains | Overweight → Overweight | — | $50.25 | $50.97 | +1.4% | +6.8% | -1.7% | -2.0% | +3.8% | -0.7% |
| Feb 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $50.25 | $50.97 | +1.4% | +6.8% | -1.7% | -2.0% | +3.8% | -0.7% |
| Feb 21 | Canaccord Genuity | Maintains | Buy → Buy | — | $47.87 | $47.96 | +0.2% | +0.6% | +1.5% | +1.2% | +1.6% | +6.8% |
| Feb 16 | Wedbush | Maintains | Neutral → Neutral | — | $46.26 | $47.00 | +1.6% | +5.8% | -2.1% | +0.6% | +1.5% | +1.2% |
| Feb 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $45.66 | $46.32 | +1.4% | +1.3% | +5.8% | -2.1% | +0.6% | +1.5% |
| Jan 30 | Baird | Maintains | Outperform → Outperform | — | $45.99 | $46.21 | +0.5% | -2.4% | -1.7% | -0.0% | -2.4% | +4.0% |
| Jan 19 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $43.16 | $43.36 | +0.5% | +3.3% | +0.1% | -0.3% | -2.0% | +3.8% |
| Nov 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $36.60 | $36.79 | +0.5% | +6.1% | -2.7% | +0.8% | -4.8% | -3.6% |
| Oct 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.18 | $32.00 | -0.6% | +2.0% | +5.1% | -4.9% | +0.8% | +7.0% |
| Oct 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $35.68 | $35.69 | +0.0% | +2.6% | -0.9% | -10.0% | +2.8% | +10.3% |
| Sep 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $36.43 | $36.17 | -0.7% | +0.7% | +2.0% | -1.3% | -4.7% | +1.4% |
| Aug 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $41.30 | $41.09 | -0.5% | -8.8% | -4.1% | -2.6% | +4.7% | -0.8% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.12 | $42.93 | -0.4% | -0.5% | -1.3% | -2.5% | -8.8% | -4.1% |
| Jun 7 | Citigroup | Maintains | Buy → Buy | — | $51.48 | $51.91 | +0.8% | +0.7% | -0.5% | -0.4% | +0.0% | +1.2% |
| Jun 6 | Evercore ISI | Upgrade | In Line → Outperform | — | $51.25 | $54.01 | +5.4% | +0.4% | +0.7% | -0.5% | -0.4% | +0.0% |
| Jun 6 | Wedbush | Maintains | Neutral → Neutral | — | $51.25 | $54.01 | +5.4% | +0.4% | +0.7% | -0.5% | -0.4% | +0.0% |
| May 8 | Wedbush | Maintains | Neutral → Neutral | — | $47.22 | $47.22 | +0.0% | -0.4% | +0.0% | +3.2% | -3.0% | -0.0% |
| May 5 | Credit Suisse | Maintains | Outperform → Outperform | — | $45.81 | $43.98 | -4.0% | +3.1% | -0.4% | +0.0% | +3.2% | -3.0% |
| May 5 | Citigroup | Maintains | Buy → Buy | — | $45.81 | $43.98 | -4.0% | +3.1% | -0.4% | +0.0% | +3.2% | -3.0% |
| Apr 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.85 | $43.76 | +4.6% | +1.1% | +0.3% | +2.8% | +0.8% | -3.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 1,899 | $24.62 | $47K | 94,462 | -2.09% | — |
| Jun 15, 2026 | Sanders Corazon (Corsee) D. | — | Sell | 2,000 | $25.05 | $50K | 21,095 | -2.09% | — |
| Jun 1, 2026 | Horn Howard | Chief Financial Officer | Sell | 4,653 | $23.77 | $111K | 105,689 | -4.68% | -1.46% |
| May 18, 2026 | SULIMAN SHEHNAAZ | — | Sell | 5,740 | $25.12 | $144K | 27,951 | -7.19% | -1.07% |
| May 5, 2026 | Crombez Eric | EVP and Chief Medical Officer | Sell | 344 | $24.96 | $9K | 111,189 | +0.77% | -1.42% |
| May 1, 2026 | Horn Howard | Chief Financial Officer | Sell | 4,683 | $24.90 | $117K | 110,342 | +0.81% | +0.69% |
8-K · 2.02
!! High
Ultragenyx Pharmaceutical Inc. -- 8-K 2.02: Earnings Results
Ultragenyx Pharmaceutical reported earnings results that investors can review in the attached press release for insights into operational performance and financial condition.
May 5
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Unilife's UX111 product received regulatory approval, positioning the company for commercial launch, but investors should monitor manufacturing execution risks and whether the product meets durability expectations in real-world use.
Apr 2
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
RARE's clinical trial for its gene therapy will measure muscle strength outcomes through 48 weeks, providing critical efficacy data that could support regulatory approval and significantly impact the stock's valuation trajectory.
Mar 30
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Rare Genomics' experimental OTC deficiency treatment demonstrated clinically meaningful improvements in 64-71% of patients at Week 24, substantially outperforming placebo, potentially supporting regulatory approval and market opportunity for this rare disease indication.
Mar 12
8-K · 8.01
!! High
Ultragenyx Pharmaceutical Inc. -- 8-K 8.01: Material Event / Announcement
Ultragenyx Pharmaceutical's gene therapy DTX401 received FDA priority review for GSD Ia treatment, with an approval decision expected by August 2026, potentially enabling a significant new revenue stream.
Feb 23
8-K
Ultragenyx Pharmaceutical Inc. -- 8-K Filing
Ultragenyx Pharmaceutical will record significant charges in early 2026 related to terminating UX143 manufacturing agreements, signaling a strategic shift in the company's pipeline or manufacturing priorities.
Feb 12
8-K · 8.01
!! High
Ultragenyx Pharmaceutical Inc. -- 8-K 8.01: Material Event / Announcement
Ultragenyx Pharmaceutical's UX111 gene therapy demonstrated durable biomarker improvements and functional benefits in trial results, supporting potential regulatory approval and market expansion for this rare disease treatment.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Portfolio Management Llc | 5,385,992 | $113M | New | Mar 2026 |
| 2 | Aqr Capital Management Llc | 4,578,024 | $96M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 4,189,831 | $88M | New | Mar 2026 |
| 4 | Morgan Stanley | 3,652,590 | $84M | Added | Dec 2025 |
| 5 | Rtw Investments, Lp | 3,648,795 | $76M | Added | Mar 2026 |
| 6 | Sands Capital Management, Llc | 3,214,533 | $67M | Reduced | Mar 2026 |
| 7 | Bellevue Group Ag | 2,380,000 | $50M | Added | Mar 2026 |
| 8 | Assenagon Asset Management S.a. | 2,257,671 | $47M | Added | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 2,205,820 | $46M | Added | Mar 2026 |
| 10 | Frontier Capital Management Co Llc | 1,965,084 | $45M | Added | Dec 2025 |
| 11 | Citadel Advisors Llc | 2,115,491 | $44M | Reduced | Mar 2026 |
| 12 | Millennium Management | 1,772,184 | $37M | Added | Mar 2026 |
| 13 | Pictet Asset Management Holding Sa | 1,231,331 | $27M | Reduced | Dec 2025 |
| 14 | D.e. Shaw & Co | 1,261,018 | $26M | Added | Mar 2026 |
| 15 | Jones Hill Capital Lp | 1,165,557 | $24M | New | Mar 2026 |
| 16 | Jane Street Group, Llc | 1,021,499 | $23M | Added | Dec 2025 |
| 17 | Bank Of America Corp /de/ | 1,046,546 | $22M | Added | Mar 2026 |
| 18 | Qube Research & Technologies Ltd | 914,760 | $19M | New | Mar 2026 |
| 19 | Point72 Asset Management | 893,295 | $19M | New | Mar 2026 |
| 20 | Candriam S.c.a. | 799,384 | $18M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.86B
Enterprise Value
$3.34B
P/E (TTM)
-4.75x
Forward P/E
—
PEG Ratio
0.54x
P/B
—
P/S
4.28x
P/FCF
-6.06x
EV/EBITDA
—
Shares Out
98.6M
Financials (TTM)
Revenue
$669.4M
Net Income
-$609.4M
EBITDA
-$503.3M
Free Cash Flow
-$472.0M
Op Cash Flow
-$466.0M
EPS Basic
$-5.83
EPS Diluted
$-6.11
EPS Forward
$-4.42
Gross Margin
83.6%
Op Margin
-83.9%
Net Margin
-91.0%
Balance Sheet
Total Assets
$1.53B
Total Liab.
$1.60B
Total Equity
-$73.0M
Cash
$693.0M
LT Debt
$1.17B
Book Value/Sh
$-0.74
Debt/Equity
-15.95x
Current Ratio
2.48
Quick Ratio
2.34
Returns & Growth
ROE
718.8%
ROA
-37.5%
ROIC
-43.5%
Rev Growth YoY
+20.1%
EPS Growth YoY
+7.3%
Price Returns
2W
-7.2%
1M
-3.0%
3M
+2.4%
6M
-31.1%
12M
-29.7%
Technicals
52W High
$41.44
52W Low
$18.50
50d MA
$24.42
200d MA
$27.02
RSI (14)
74.10
ATR (14)
$1.27
Beta
0.25
Avg Volume
1.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$51.50
High
$67.00
Low
$34.00
Median
$51.00
Data updated apr 26, 2026 9:54pm
· Source: financialmodelingprep.com